Skip to main content

Table 1 Subject characteristics

From: Changes over time in inflammatory and structural lesions at the sacroiliac joint in children with spondyloarthritis exposed and unexposed to tumor necrosis factor inhibitor

  All subjects TNFi exposed TNFi unexposed
(N = 46) (N = 23) (N = 23)
Age, years (Median, IQR) 13.6 (11.4, 15.4) 13.1 (11.4, 15.3) 13.9 (11.4, 15.4)
Sex, male 29 (63.04%) 13 (56.52%) 16 (69.57%)
Race, white 30 (71.43%) [N = 42] 16 (72.73%) [N = 22] 14 (70.00%) [N = 20]
HLA-B27 positive 23 (50.00%) 14 (60.87%) 9 (39.13%)
Hip arthritis 12 (26.09%) 8 (34.78%) 4 (17.39%)
Lower back pain 27 (58.70%) 12 (52.17%) 15 (65.22%)
Morning stiffness (> 15 min) 20 (45.45%) [N = 44] 10 (45.45%) [N = 22] 10 (45.45%) [N = 22]
Disease duration, months (Median, IQR) 11.3 (3.7, 23.7) 9.5 (2.9, 20.3) 12.0 (3.9, 36.2)
Active peripheral joint count (Median, IQR) 0.0 (0.0, 2.0) 0.0 (0.0, 2.0) 0.0 (0.0, 2.0)
Tender entheses (Median, IQR) 1.5 (0.0, 4.0) 0.0 (0.0, 5.0) 2.0 (0.0, 4.0)
Physician global (0–10; Median, IQR) 2.0 (2.0, 4.0) [N = 34] 2.0 (2.0, 4.0) [N = 21] 2.0 (1.0, 3.0) [N = 13]
Patient global (0–10; Median, IQR) 4.3 (2.0, 6.0) [N = 30] 5.0 (3.0, 6.0) [N = 19] 2.0 (1.0, 7.0) [N = 11]
Patient pain (0–10; Median, IQR) 5.0 (1.6, 7.0) [N = 30] 5.6 (2.0, 7.0) [N = 19] 3.0 (1.0, 7.0) [N = 11]
csDMARD use during follow-up 17 (36.96%) 8 (34.78%) 9 (39.13%)
Non-TNFi bDMARD use during follow-up* 4 (8.70%) 4 (17.39%) 0 (0.00%)
NSAID use during follow-up 32 (69.57%) 12 (52.17%) 20 (86.96%)
  1. Legend. *There were four patients exposed to a non-TNFi bDMARD; all were also TNFi-exposed. Three of four started the TNFi first and of those, two did not start the non-TNFi until after the second MRI that was used for the change in inflammation assessment